Bausch + Lomb (NYSE:BLCO) Stock Price Target Raised at Royal Bank Of Canada

Bausch + Lomb (NYSE:BLCO) had its price objective raised by equities research analysts at Royal Bank Of Canada from $21.00 to $23.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price would suggest a potential upside of 12.04% from the stock’s current price.

Several other analysts also recently commented on BLCO. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $20.00 price objective on shares of Bausch + Lomb in a research note on Thursday. Citigroup restated a “buy” rating on shares of Bausch + Lomb in a report on Thursday. Wells Fargo & Company upped their target price on shares of Bausch + Lomb from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

Bausch + Lomb Stock Up 0.6%

BLCO stock traded up $0.13 during trading on Thursday, reaching $20.53. The stock had a trading volume of 2,654,697 shares, compared to its average volume of 462,677. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. The firm has a fifty day moving average price of $17.24 and a 200 day moving average price of $16.66. The company has a market capitalization of $7.34 billion, a P/E ratio of -42.60, a PEG ratio of 0.55 and a beta of 0.56. Bausch + Lomb has a 1-year low of $14.44 and a 1-year high of $21.36.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.13. The business had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.37 billion. Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.18 EPS. On average, equities analysts anticipate that Bausch + Lomb will post 0.81 earnings per share for the current year.

Insiders Place Their Bets

In other Bausch + Lomb news, CAO Frederick Munsch sold 52,900 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the transaction, the chief accounting officer directly owned 45,831 shares in the company, valued at $769,044.18. The trade was a 53.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $16.50, for a total value of $206,250.00. Following the completion of the sale, the director directly owned 69,792 shares in the company, valued at $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 71,459 shares of company stock worth $1,194,370 in the last 90 days. 1.45% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds have recently made changes to their positions in BLCO. Whitebox Advisors LLC raised its position in shares of Bausch + Lomb by 15.8% in the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after acquiring an additional 150,641 shares in the last quarter. Beach Point Capital Management LP bought a new position in shares of Bausch + Lomb during the 3rd quarter worth approximately $5,882,000. Sei Investments Co. grew its position in shares of Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock worth $2,214,000 after buying an additional 69,633 shares during the period. Engineers Gate Manager LP bought a new position in Bausch + Lomb during the second quarter worth $1,479,000. Finally, Dimensional Fund Advisors LP grew its holdings in Bausch + Lomb by 13.2% in the first quarter. Dimensional Fund Advisors LP now owns 85,779 shares of the company’s stock worth $1,362,000 after purchasing an additional 9,971 shares during the period. 11.07% of the stock is currently owned by institutional investors.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q3 earnings beat expectations: Adjusted EPS was $0.34, well above the $0.21–$0.22 analyst consensus and up from $0.18 a year earlier. Revenue reached approximately $1.38 billion, slightly ahead of estimates and 7.3% higher year over year. Bausch + Lomb Q3 earnings beat estimates
• Positive Sentiment: Full-year guidance was raised: Management now expects 2026 revenue of $5.450 billion to $5.550 billion and adjusted EBITDA of $1.090 billion to $1.140 billion, citing continued momentum from its Vision ’27 strategy and growth in eye-care products. Bausch + Lomb raises 2026 guidance
• Positive Sentiment: Profitability improved: The company swung to a quarterly profit on an adjusted basis, with earnings growth outpacing revenue growth. This stronger operating performance is the primary reason investors are reacting favorably to the latest updates. Bausch + Lomb swings to profit and raises guidance

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.